Your browser doesn't support javascript.
loading
Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus.
Ayers, Victoria B; Huang, Yan-Jang S; Kohl, Alain; Dunlop, James I; Hettenbach, Susan M; Park, So Lee; Higgs, Stephen; Vanlandingham, Dana L.
  • Ayers VB; Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA.
  • Huang YS; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas, USA.
  • Kohl A; Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA.
  • Dunlop JI; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas, USA.
  • Hettenbach SM; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom.
  • Park SL; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom.
  • Higgs S; Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA.
  • Vanlandingham DL; Biosecurity Research Institute, Kansas State University, Manhattan, Kansas, USA.
Viral Immunol ; 36(1): 41-47, 2023 01.
Article en En | MEDLINE | ID: mdl-36622942
Cache Valley virus (CVV) is a mosquito-borne bunyavirus that is enzootic throughout the new world. Although CVV is known as an important agricultural pathogen, primarily associated with embryonic lethality and abortions in ruminants, it has recently been recognized for its expansion as a zoonotic pathogen. With the increased emergence of bunyaviruses with human and veterinary importance, there have been significant efforts dedicated to the development of bunyavirus vaccines. In this study, the immunogenicity of a candidate live-attenuated vaccine (LAV) for CVV, which contains the deletion of the nonstructural small (NSs) and nonstructural medium (NSm) genes (2delCVV), was evaluated and compared with an autogenous candidate vaccine created through the inactivation of CVV using binary ethylenimine (BEI) with an aluminum hydroxide adjuvant (BEI-CVV) in sheep. Both 2delCVV and BEI-CVV produced a neutralizing antibody response that exceeds the correlate of protection, that is, plaque reduction neutralization test titer >10. However, on day 63 postinitial immunization, 2delCVV was more immunogenic than BEI-CVV. These results warrant further development of 2delCVV as a candidate LAV and demonstrate that the double deletion of the NSs and NSm genes can be applied to the development of vaccines and as a common attenuation strategy for orthobunyaviruses.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus Bunyamwera / Vacunas Virales Límite: Animals / Female / Humans / Pregnancy Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus Bunyamwera / Vacunas Virales Límite: Animals / Female / Humans / Pregnancy Idioma: En Año: 2023 Tipo del documento: Article